BCAX (Bicara Therapeutics) Research & Development: $138.26 Mil (TTM As of Mar. 2026)


BCAX Bicara Therapeutics Inc BCAX
12 GF Score
Price $28.37
! 3 Warning Signs
View Full Analysis

What is Bicara Therapeutics Research & Development?

Bicara Therapeutics BCAX +5.58% 12 Research & Development is $138.26 Mil as of Mar. 2026. GuruFocus rates BCAX with a GF Score™ of 12/100. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Bicara Therapeutics's Research & Development for the three months ended in Mar. 2026 was $47.50 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $138.26 Mil.

Bicara Therapeutics  (NAS:BCAX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Bicara Therapeutics Research & Development Related Terms

Bicara Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Bicara Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bicara Therapeutics Research & Development Chart

Bicara Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Research & Development
31.31 30.62 63.62 125.10

Bicara Therapeutics Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.33 24.80 32.98 32.99 47.50
BCAX
12GF Score
Bicara Therapeutics Inc BCAX
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bicara Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $138.26 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $138.26 Mil mean?
Bicara Therapeutics (BCAX) has a Research & Development of $138.26 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Bicara Therapeutics and its competitors.
Is Bicara Therapeutics' Research & Development too high?
Bicara Therapeutics' current Research & Development is $138.26 Mil. Overall, Bicara Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bicara Therapeutics' Research & Development compare to ZYME and SRPT?
Bicara Therapeutics' Research & Development of $138.26 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Bicara Therapeutics and its competitors. Bicara Therapeutics's current Research & Development is $138.26 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bicara Therapeutics stock overvalued right now?
Bicara Therapeutics (BCAX) has a current Research & Development of $138.26 Mil. The current Research & Development is $138.26 Mil. Bicara Therapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Bicara Therapeutics (BCAX), the current Research & Development is $138.26 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bicara Therapeutics Business Description

Address 116 Huntington Avenue, Suite 703, Boston, MA, USA, 02116
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
12GF Score

Get the complete analysis for BCAX

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.37
Price